

# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002  
Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1<sup>st</sup> Lane Ambawadi, Ahmedabad,  
Gujarat-380006

Phone: +91-6359637788, Email: [investor.relations@kashyaptele-medicines.com](mailto:investor.relations@kashyaptele-medicines.com),

Website: [www.kashyaptele-medicines.com](http://www.kashyaptele-medicines.com)

---

Date: 09<sup>th</sup> November, 2022

To,  
BSE Limited  
Listing Department,  
Phiroz Jeejeebhoy Tower,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai-400 001

Scrip Code – 531960

Sub.: Outcome of Board Meeting held on 09<sup>th</sup> November, 2022 as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to above and as per intimation given for meeting of the Board of Directors, we are pleased to inform that above referred meeting was held on 09<sup>th</sup> November, 2022 wherein Board of Directors has considered and approved, inter alia:

1. unaudited Financial Results and statement of assets and liabilities along with Limited Review Report thereon as received from the Statutory Auditors of the Company for the second quarter and half year ended 30<sup>th</sup> September, 2022 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and
2. all other businesses as per agenda circulated.


The Meeting of the Board of Directors commenced at 1.00 p.m. and concluded at 1.40 p.m.

Kindly take the above disclosures on your record as compliance with Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take note of the same.

Thanking you.

Yours faithfully,  
FOR, KASHYAP TELE-MEDICINES LIMITED

  
PARITOSH TRIVEDI  
COMPANY SECRETARY



Encl: As above



# SAREMAL & CO


## Chartered Accountants

CA Saremal Shah (Bcom, FCA); CA Pravin Lavana (Bcom, LLB, FCA)

**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE QUARTERLY UNAUDITED FINANCIAL RESULTS AND STATEMENT OF ASSETS AND LIABILITIES FOR THE SECOND QUARTER AND HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER, 2022 OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED**

To  
The Board of Directors,  
**KASHYAP TELE-MEDICINES LIMITED**  
**AHMEDABAD**

1. We have reviewed the accompanying statement of Un-audited Financial Results and Statement of Assets and Liabilities of **M/S KASHYAP TELE-MEDICINES LIMITED** (the Company) for the second quarter and half year ended 30<sup>th</sup> September, 2022 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended (the 'Listing Regulations'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29<sup>th</sup> March, 2019 and SEBI Circular No. CIR/CFD/CMD1/80/2019 dated 19<sup>th</sup> July, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Statement on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial Results and Statement of Assets and Liabilities are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results and statement of Assets and Liabilities prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.  
Our Conclusion is not modified in respect of this matter.



For SAREMAL & CO.  
CHARTERED ACCOUNTANTS

PRAVIN LAVANA  
(PARTNER)

MEMBERSHIP NO.: 037180  
FIRM REGISTRATION NO.: 109281W  
UDIN No.: 22037180BCPGDL4472

Ahmedabad, 09<sup>th</sup> November, 2022

# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002

Corp. Off.: UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2022 (As per Regulation 33 of SEBI (LODR) Regulations, 2015 & Schedule III Companies Act, 2013 read with IND-AS)

(Rs in Lakhs Except EPS)

S.No.	Particulars	Quarter Ended (Standalone)			Half Year Ended		Year Ended
		30-09-2022	30-06-2022	30-09-2021	30-09-2022	30-09-2021	31-03-2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from operations	5.10	5.30	4.75	10.40	9.75	19.55
II	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
III	<b>Total Revenue ( I + II )</b>	<b>5.10</b>	<b>5.30</b>	<b>4.75</b>	<b>10.40</b>	<b>9.75</b>	<b>19.55</b>
IV	<b>Expenses</b>						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(d) Employee benefits expense	2.46	2.55	2.22	5.01	4.43	9.27
	(e) Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00	0.00
	(g) Other expenses	2.46	1.98	1.97	4.44	3.86	20.69
	<b>Total expenses</b>	<b>4.92</b>	<b>4.53</b>	<b>4.19</b>	<b>9.45</b>	<b>8.29</b>	<b>29.96</b>
V	<b>Profit before exceptional and extraordinary items and tax (III-IV)</b>	<b>0.18</b>	<b>0.77</b>	<b>0.56</b>	<b>0.95</b>	<b>1.46</b>	<b>(10.41)</b>
VI	Exceptional and Extraordinary Items	0.00	0.00	0.00	0.00	0.00	(162.46)
VII	<b>Profit Before Tax ( V- VI )</b>	<b>0.18</b>	<b>0.77</b>	<b>0.56</b>	<b>0.95</b>	<b>1.46</b>	<b>(172.87)</b>
VIII	<b>Tax Expense :-</b>						
	(a) Current Tax	0.05	0.19	0.12	0.24	0.33	0.00
	(b) Tax relating to pervious period	0.00	0.00	0.00	0.00	0.00	(0.11)
	<b>Total Tax Expense</b>	<b>0.05</b>	<b>0.19</b>	<b>0.12</b>	<b>0.24</b>	<b>0.33</b>	<b>(0.11)</b>
IX	<b>Profit / (Loss) for the period from Continuing Operations (VII-VIII)</b>	<b>0.13</b>	<b>0.58</b>	<b>0.44</b>	<b>0.71</b>	<b>1.13</b>	<b>(172.76)</b>
X	Profit/(Loss) from Discontinuing Operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of Discontinuing Operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(Loss) from Discontinuing Operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	<b>Profit / (Loss) for the period (IX + XII )</b>	<b>0.13</b>	<b>0.58</b>	<b>0.44</b>	<b>0.71</b>	<b>1.13</b>	<b>(172.76)</b>
XIV	Share of Profit / (Loss) of Associates	N.A	N.A	N.A	N.A	N.A	N.A
XV	Minority Interest	N.A	N.A	N.A	N.A	N.A	N.A
XVI	<b>Profit / (Loss) after Taxes, minority interest and share of profit / (loss) of associates</b>	<b>0.13</b>	<b>0.58</b>	<b>0.44</b>	<b>0.71</b>	<b>1.13</b>	<b>(172.76)</b>
XVII	<b>Other Comprehensive Income</b>						
	A. Items that will be/will not be reclassified to profit and loss						
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	<b>Total comprehensive income for the period (XVI+XVII)</b>	<b>0.13</b>	<b>0.58</b>	<b>0.44</b>	<b>0.71</b>	<b>1.13</b>	<b>(172.76)</b>
XIX	<b>Paid-up Equity Share Capital (Face Value of Rs. 1/- each)</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>
XXI	<b>Earnings per equity Share: (not annualised)</b>	<b>0.000</b>	<b>0.001</b>	<b>0.000</b>	<b>0.001</b>	<b>0.002</b>	<b>-0.362</b>
	(a) Basic and Diluted EPS (XVI/XIX)						

### Notes:

- The above Unaudited Financial Results of the company for the quarter ended on 30th September, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors in the Meeting held on 09th November, 2022
- The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Ind As') from 1st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and discloses the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India ( Listing Obligations and Disclosures Requirements) Regulation, 2015 ( as amended).
- The Statutory Auditors of the Company have carried out Limited Review of the above unaudited Financial Results and Statement of Assets & Liabilities for the quarter and half year ended on 30th September, 2022 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
- Pursuant to compliance of SEBI notification No. SEBI/LAD-NRO/GN/2018/1 dated 9<sup>th</sup> May, 2018 , a Statement Of Cash Flows for the Half Year ended 30th September, 2022 has also been submitted by way of a note as enclosed herewith as Annexure-A.
- A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).
- The company is engaged in single segment therefore has only one reportable segment in accordance with Ind AS 108 'Operating Segments'.
- Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.

Place : Ahmedabad  
Date : 09th November, 2022



For and on behalf of Board of Directors of  
Kashyap Tele- Medicines Limited



*(Signature)*

Raghav Agrawal  
Director/Chief Financial Officer  
DIN: 02264149

# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : "Suryarath", 1st Floor, Panchwati, 1st Lane, Ambawadi, Ahmedabad – 380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

## STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2022

(As per Regulation 33 of SEBI (LODR) Regulations, 2015 & Schedule III Companies Act, 2013 read with IND-AS)

	(Rs. In Lakhs)	
Particulars	As at 30-09-2022 (Unaudited)	As at 31-03-2022(Audited)
<b>I Non-Current Assets</b>		
(a) Property, Plant and Equipment	-	-
(b) Capital work in progress	-	-
(c) Financial Assets	-	-
(i) Investments	-	-
(ii) Other Financial Assets	0.34	0.34
(d) Other Non-Current Assets	64.43	64.43
	<b>64.77</b>	<b>64.77</b>
<b>II Current Assets</b>		
(a) Inventories	-	-
(b) Financial Assets	-	-
(i) Trade Receivables	0.60	-
(ii) Cash and Cash Equivalents	0.87	2.12
(iii) Investments	-	-
(iv) Loans	-	-
(c) Other Current Assets	-	0.72
(d) Accrued Interest - FDR	2.73	0.02
	<b>4.20</b>	<b>2.86</b>
<b>TOTAL ASSETS</b>	<b>68.97</b>	<b>67.63</b>
<b>I Equity</b>		
(a) Share Capital	477.22	477.22
(b) Other Equity	(409.85)	(410.56)
	<b>67.37</b>	<b>66.66</b>
<b>II Non Current Liabilities</b>		
(a) Long term borrowings	-	-
(b) Deferred tax liabilities (net)	-	-
(c) Other long term liabilities	-	-
<b>III Current Liabilities</b>		
(a) Financial liabilities		
(i) Short term borrowings	0.10	-
(ii) Trade Payables	-	-
Total Outstanding dues of micro enterprises and small enterprises	-	-
Total Outstanding dues of creditors other than micro enterprises and small enterprises	-	-
(iii) Other Financial liabilities	1.22	0.97
(b) Other Current Liabilities	0.04	-
(c) Short-Term Provisions	-	-
(d) Income tax liabilities	0.24	-
	<b>1.60</b>	<b>0.97</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>68.97</b>	<b>67.63</b>

Place : Ahmedabad  
Date : 09th November, 2022



For and on behalf of Board of Directors of  
Kashyap Tele - Medicines Limited



*(Signature)*

Raghav Agrawal  
Director/Chief Financial Officer

DIN: 02264149

**KASHYAP TELE-MEDICINES LIMITED**

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

**STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2022**

(As per Schedule III Companies Act, 2013 and IND-AS)

(Rs. In Lakhs)

	Particulars	For the Year ended	
		30-09-2022	31-03-2022
<b>A</b>	<b>Cash flow from operating activities:</b>		
	Profit before tax	0.95	(172.88)
	<b>Adjustments</b>		
	Exceptional items	0.00	162.47
	<b>Operating profit before working capital changes</b>	<b>0.95</b>	<b>(10.41)</b>
	<b>Adjustments for changes in working capital :</b>		
	Change in trade receivables	(0.60)	14.44
	Change in other receivables	(1.99)	(15.06)
	Change in Current Liabilities & other payables	0.63	(0.40)
	<b>Cash flow from/ (used in) operations</b>	<b>(1.01)</b>	<b>(11.43)</b>
	Income taxes paid	0.24	(0.10)
	<b>Net cash flow from/(used in) operating activities</b>	<b>(1.25)</b>	<b>(11.33)</b>
<b>B</b>	<b>Cash flow from investing activities:</b>		
	Purchase of fixed assets (including capital work-in-progress, capital advances and intangibles under development)	-	-
	Proceeds from sale of fixed assets	-	-
	Purchase of investments	-	-
	Proceeds from sale of investments	-	-
	Net proceeds (to)/from loans and advances	-	-
	Net proceeds (to)/from deposits	-	-
	Dividend received	-	-
	Interest received	-	-
	<b>Net cash (used in)/flow from investing activities</b>	<b>0.00</b>	<b>0.00</b>
<b>C</b>	<b>Cash flow from financing activities:</b>		
	Net (repayment)/proceeds from short-term borrowings	-	-
	Repayment of short-term borrowings	-	-
	Proceeds from long-term borrowings	-	-
	Repayment of long-term borrowings	-	-
	Interest paid	-	-
	<b>Net cash (used in)/flow from financing activities:</b>	<b>0.00</b>	<b>0.00</b>
<b>D</b>	<b>Net increase in cash and cash equivalents</b>	<b>(1.25)</b>	<b>(11.33)</b>
	Cash and cash equivalents at the beginning of the year	2.12	13.45
	Cash and cash equivalents at the end of the year	0.87	2.12

Place : Ahmedabad

Date : 09th November, 2022

For and on behalf of Board of Directors of  
Kashyap Tele - Medicines Limited

Raghav Agrawal  
Director/Chief Financial Officer  
DIN: 02264149